Embed Size (px)
Citation preview
Curriculum Vitae
Revised 4/17/17 1
Chad Victor Pecot, M.D.
Education
MD Anderson Cancer Center (Houston, TX), 7/2009-6/2012, Hematology/Oncology Fellowship
Vanderbilt Medical Center (Nashville, TN), 7/2006-6/2009, Internal Medicine Residency
M.D., University of Miami (Miami, FL), 8/2002-5/2006, Scholars Program (Alpha Omega Alpha)
B.S., University of Miami (Coral Gables, FL), 8/1999-5/2002, Biomedical Engineering (Cum Laude)
Professional Experience
Assistant Professor of Medicine, UNC Hematology/Oncology Division, 2013-present
Member of UNC Cancer Center of Nanotechnology Excellence (CCNE), 2015-present
Member of UNC Center for Nanotechnology in Drug Delivery, 2014-present
Member of UNC Lineberger Comprehensive Cancer Center, 2013-present
Member of UNC Molecular Therapeutics Program, 2013-present
Member of UNC Curriculum in Genetics and Molecular Biology, 2013-present
Advanced Scholar (Instructor), Department of TH&N Oncology, MDACC, 2012-2013
Clinical Specialist, Internal Medicine, MD Anderson Cancer Center, 2009-2013
Chief Fellow, MD Anderson Cancer Center, 2011-2012
Credentials
Board Certification Medical Oncology, 11/2012
Internal Medicine, 11/2009
Licensures/Certification ACLS Certified, 5/2012
North Carolina License, 2/2015
Texas Medical License, 4/2009
Tennessee Medical License, 2/2009
Honors and Awards
Susan G. Komen Career Catalyst Award 2017
Free to Breathe Metastasis Research Award 2016
Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research 2016
William Rippe Award for Distinguished Research in Lung Cancer 2016
Lung Cancer Research Foundation Award 2016
ASCO Conquer Cancer Foundation Scientific Career Development Retreat 2016
University of North Carolina UCRF Innovator Award 2015
American Cancer Society Mentored Research Scholar Award 2014
The Jimmy V Foundation Scholar Award 2014
William Guy Forbeck Research Scholar Award 2014
The Ben F. Love Fellowship in Innovative Cancer Therapies 2012
Division of Cancer Medicine Achievement in Basic Science Research 2012
ASCO Conquer Cancer Foundation Young Investigator Award 2011
National Institute of Health, Research Loan Repayment Awardee 2011
AACR Molecular Biology in Clinical Oncology Workshop 2010
ASCO Cancer Foundation Merit Award 2010
Ruth L. Kirschstein T32 National Research Service Award 2010
Curriculum Vitae
Revised 4/17/17 2
The Jeffrey Lee Cousins Fellowship in Lung Cancer Research 2010
Inductee of Alpha Omega Alpha Honors Society 2006
American Cancer Society Creativity Team Award 2005
Thomas Brown McClelland Rotary Scholarship 2005
Thomas Brown McClelland Rotary Scholarship 2004
Peter J. Tarjan Award for Excellence in Biomedical Engineering 2002
Bibliography
Peer-Reviewed Original Research and Invited Articles
1. Jillian L. Perry, Kevin G. Reuter, J. Christopher Luft, Chad V. Pecot, William C. Zamboni, Joseph
M. DeSimone. Mediating Passive Tumor Accumulation through Particle Size, Tumor Type and
Location. Nano Letters, Ahead of Print, 2017 (PMC pending).
2. Katrien Van Roosbroeck, Francesca Fanini, Tetsuro Steoyama, Cristina Ivan, Cristian Rodriguez-
Aguayo, Enrique Fuentes-Mattei, Lianchun Xiao, Ivan Vannini, Roxana Redis, Lucilla D’Abundo,
Xinna Zhang, Milena S Nicoloso, Simona Rossi, Vianey Gonzalez-Villasana, Rajesha Rupaimoole,
Manuela Ferracin, Fortunato Morabito, Antonino Neri, Peter Ruvolo, Vivian R. Ruvolo, Chad V.
Pecot, Dino Amadori, Lynne Aruzzo, Steliana Calin, Xuemei Wang, M. James You, Alessandra
Ferrajoli, Robert Z. Orlowski, William Plunkett, Tara Lichtenberg, Ramana V. Davuluri, Ioana
Berindan-Neagoe, Massimo Negrini, Ignacio I. Wistuba, Kantarjian Hagop, Anil K. Sood, Gabriel
Lopez-Berestein, Michael J. Keating, Muller Fabbri and George A. Calin. Combining Anti-miR-155
with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, Ahead of Print,
2016 (PMC pending).
3. Monika Haemmerle, Justin Bottsford-Miller, Sunila Pradeep, Morgan L. Taylor, Hyun-Jin Choi, Jean
M. Hansen, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Alpa M. Nick, Archana S. Nagaraja,
Tony Gutschner, Kshipra M. Gharpure, Lingegowda S. Mangala, Rajesha Rupaimoole, Hee Dong
Han, Behrouz Zand, Guillermo N. Armaiz-Pena, Sherry Y. Wu, Chad V. Pecot, Alan R. Burns,
Gabriel Lopez-Berestein, Vahid Afshar-Kharghan and Anil K. Sood. FAK regulates platelet
extravasation and tumor growth after angiogenic therapy withdrawl. Journal of Clinical Investigation,
Ahead of Print, 2016. (PMC pending).
4. Salma H. Azam, Chad V. Pecot. Cancer’s Got Nerve: Schwann cells drive perineural invasion.
Journal of Clinical Investigation, 126 (4): 1242-4, 2016. PMC 4811122
5. Yinghong Pan, Gordon Robertson, Lykke Pedersen, Emilia Lim, Anadulce Hernandez-Herrera, Amy
C Rowat, Sagar L Patil, Clara K Chan, Yunfei Wen, Xinna Zhang, Upal Basu-Roy, Alka
Mansukhani, Andy Chu, Payal Sipahimalani, Reanne Bowlby, Denise Brooks, Nina Thiessen,
Yussanne Ma, Richard A. Moore, Jacquie E. Schein, Andrew J. Mungall, Chad V. Pecot, Anil K.
Sood, Steven J.M Jones, Marco A Marra, Preethi H. Gunaratne. miR-509-3p is clinically significant
and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget,
Ahead of Print, 2016. (PMC pending)
6. Sherry Wu, Rajesha Rupaimoole, Fangrong Shen, Sunila Pradeep, Chad V. Pecot, Cristina Ivan,
Archana Sidalaghatta Nagaraja, Kshipra Gharpure, Elizabeth Pham, Hiroto Hatakeyama, Michael
McGuire, Monika Haemmerle, Viviana Vidal-Anaya, Courtney Olsen, Cristian Rodriguez-Aguayo,
Justyna Filant, Ehsan Ehsanipour, Shelley Herbrich, Sourindra Maiti, Li Huang, Ji Hoon Kim, Xinna
Zhang, Hee Dong Han, Guillermo N Armaiz-Pena, Elena Seviour, Susan Tucker, Min Zhang, Da
Yang, Laurence Cooper, Rouba Ali-Fehmi, Menashe Bar-Eli, Ju-Seog Lee, Prahlad Ram, Keith
Baggerly, GABRIEL LOPEZ-BERESTEIN, Mien-Chie Hung, and Anil Sood. A miR-192-EGR1-
HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications,
Ahead of Print, 2016. PMC (pending)
Curriculum Vitae
Revised 4/17/17 3
7. Behrouz Zand, Rebecca Previs, NM Zacharias, Rajesha Rupaimoole, T Mitamura, Archana S.
Nagaraja, M Guindani, Heather J. Dalton, L Yang, J Baddour, A Achreja, Wei Hu, Chad V. Pecot,
Christina Ivan, Sherry Y. Wu, C R. McCullough, Kpshipra M. Gharpure, E Shoshan, Sunila Pradeep,
L S. Mangala, Cristian Rodriguez-Aguayo, Y Wang, Alpa M. Nick, Michael A. Davies, Guillermo
Armaiz-Pena, J Liu, Susan K. Lutgendorf, Keith A. Baggerly, M B. Eli, Gabriel Lopez-Berestein, D
Nagrath, P K. Bhattacharya, Anil K. Sood. Role of Increased n-acetylaspartate Levels in Cancer.
Journal of National Cancer Institute, 108 (6), 2016. PMC (pending)
8. Rajesha Rupaimoole, Cristina Ivan, Da Yang, Kshipra M. Gharpure, Sherry Y. Wu, Chad V. Pecot,
Rebecca A. Previs, Archana S. Nagaraja, Guillermo N. Armaiz-Pena, Michael McGuire, Sunila
Pradeep, Lingegowda S. Mangala, Cristian Rodriguez-Aguayo, Li Huang, Menashe Bar-Eli, Wei
Zhang, Gabriel Lopez-Berestein, George A. Calin, Anil K. Sood. Hypoxia-upregulated microRNA-
630 targets Dicer, leading to increased tumor progression. Oncogene, Ahead of Print, 2016. PMC
4215647
9. Chad V. Pecot*, Yanyan Lou*, Hai T. Tran, Vikki J. DeVito, Xi Ming Tang, Raja Luthra, John V.
Heymach, Ignacio I. Wistuba, Zhuang Zuo, Anne S. Tsao. Germline Mutation of T790M and
Dual/Multiple EGFR Mutations in Patients with Lung Adenocarcinoma. Clinical Lung Cancer,
Ahead of Print, 2015. PMC (pending). *Contributed Equally
10. Benjamin Shields, Chad V. Pecot, Hua Gao, Malia Potts, Christa Nagel, Scott Purinton, Ying Wang,
Cristina Ivan, Hyun Kim, Robert Borkowski, Shaheen Khan, Cristian Rodriguez-Aguayo, Gabriel
Lopez-Berestein, Jayanthi Lea, Adi Gazdar, Keith Baggerly, Anil Sood, and Michael White. A
genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
Molecular Systems Biology, Ahead of Print, 2015. PMC 4704493
11. Sunila Pradeep, Jie Huang, Edna M. Mora, Alpa M. Nick, Min Soon Cho, Sherry Y. Wu, Kyunghee
Noh, Chad V. Pecot, Rajesha Rupaimoole, Martin A. Stein, Stephan Brock, Yunfei Wen, Chiyi
Xiong, Kshipra Gharpure, Jean M. Hansen, Archana S. Nagaraja, Rebecca A. Previs, Pablo Vivas-
Mejia, Hee Dong Han, Wei Hu, Lingegowda S. Mangala, Behrouz Zand, Loren J. Stagg, John E.
Ladbury, Bulent Ozpolat, S. Neslihan Alpay, Masato Nishimura, Rebecca L. Stone, Koji Matsuo,
Guillermo N. Armaiz-Peña, Heather J. Dalton, Christopher Danes, Blake Goodman, Cristian
Rodriguez-Aguayo, Carola Kruger, Armin Schneider, Shyon Haghpeykar, Padmavathi Jaladurgam,
Mien-Chie Hung, Robert L. Coleman, Jinsong Liu, Chun Li, Diana Urbauer, Gabriel Lopez-
Berestein, David B. Jackson, Anil K. Sood. Erythropoietin Stimulates Tumor Growth via EphB4.
Cancer Cell, 2015. PMC (pending)
12. Elena G. Seviour, Vasudha Sehgal, Yiling Lu, Zijun Luo, Tyler Moss, Fan Zhang, Steven Hill,
Robert Azencot, Gabriel Lopez-Berestein, Cristian Rodriguez-Aguayo, Rajesha Rupaimoole, Chad
Pecot, Anil K. Sood, Sach Mukerjee, Joe W. Gray, Gordon B. Mills, Prahlad T. Ram. Functional
proteomics identifies miRNAs to target a p27/Myc/phosphor-Rb signature in breast and ovarian
cancer. Oncogene, 2015. PMC (pending)
13. Guoyan Liu, Da Yang, Rajesha Rupaimoole, Chad V. Pecot, Yan Sun, Lingegowda S. Mangala, Xia
Li, Ping Ji, David Cogdell, Limei Hu, Yingmei Wang, Cristian Rodriguez-Aguayo, Gabriel Lopez-
Berestein, Ilya Shmulevich, Loris De Cecco, Kexin Chen, Delia Mezzanzanica, Fengxia Xue, Anil K.
Sood, and Wei Zhang. Augmentation of response to chemotherapy by microRNA-506 through
regulation of RAD51 in serous ovarian cancers. Journal of the National Cancer Institute, 2015. PMC
(pending)
14. Justin Bottsford-Miller, Hyun-Jin Choi, Heather J. Dalton, Rebecca L. Stone, Minsoon Cho, Monika
Haemmerle, Alpa M. Nick, Sunila Pradeep, Behrouz Zand, Rebecca Previs, Chad V. Pecot, Erin
King Crane, Wei Hu, Susan Lutgendorf, Vahid Afshar-Kharghan and Anil K. Sood. Differential
platelet levels affect response to taxane-based therapy in ovarian cancer. Clinical Cancer Research,
Curriculum Vitae
Revised 4/17/17 4
21(3):602-10, 2015. PMC4315757
15. Chad V. Pecot, Sherry Y. Wu, Seth Bellister, Rajat Bhattacharya, Anshumaan Maharaj, Cristian
Rodriguez-Aguayo, Maria Pia Morelli, Rajesha Rupaimoole, Vianey Gonzalez-Villasana, Behrouz
Zand, Heather J. Dalton, Scott Kopetz, Gabriel Lopez-Berestein, Lee M. Ellis, Anil K. Sood.
Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Molecular Cancer
Therapeutics, 13(12), 2876-85, 2014. PMC 4416486
16. Rajesha Rupaimoole, Sherry Y Wu, Sunila Pradeep, Cristina Ivan, Chad V. Pecot, Kshipra M.
Gharpure, Archana S. Nagaraja, Guillermo N. Armaiz-Pena, Michael McGuire, Behrouz Zand,
Heather J. Dalton, Justyna Filant, Justin Bottsford-Miller, Chunhua Lu, Nouara C. Sadaoui,
Lingegowda S. Mangala, Morgan Taylor, Twan van den Beucken, Elizabeth Koch, Cristian
Rodriguez-Aguayo, Li Huang, Menashe Bar-Eli, Bradly G. Wouters, Milan Radovich, Mircea Ivan,
George A. Calin, Wei Zhang, Gabriel Lopez-Berestein, Anil K. Sood. Hypoxia Mediated
Downregulation of miRNA Biogenesis Leads to Increased Tumor Progression. Nature
Communications, 5: 5202, 2014. PMC4215647
17. Twan van den Beucken, Elizabeth Koch, Kenneth Chu, Rajesha Rupaimoole, Peggy Prickaerts,
Michiel Adriaens, Jan Willem Voncken, Adrian L. Harris, Francesca M. Buffa, Syed Haider, Maud
H.W. Starmans, Cindy Q. Yao, Mircea Ivan, Cristina Ivan, Chad V. Pecot, Paul C. Boutros, Anil K.
Sood, Marianne Koritzinsky, Bradly G. Wouters. Hypoxia promotes stem cell phenotypes and poor
prognosis through epigenetic regulation of DICER. Nature Communications, 5: 5203, 2014.
PMC4255228
18. Pradeep Chaluvally-Raghavan, Fan Zhang, Sunila Pradeep, Mark P. Hamilton, Xi Zhao, Rajesha
Rupaimoole, Tyler Moss, Yiling Lu, Shuangxing Yu, Chad V. Pecot, Miriam R. Aure, Sylvain
Peuget, Cristian Rodriguez-Aguayo, Hee-Dong Han, Dong Zhang, Wenbin Liu, Avinashnarayan
Venkatanarayan, Marit Krohn, Gabriel Lopez-Berestein, Vessela N. Kristensen, Mihai Gagea,
Prahlad Ram, Philip L. Lorenzi, Anne-Lise Børresen-Dale, Koei Chin, Joe Gray, Nelson J. Dusetti,
Sean E. McGuire, Elsa R Flores, Anil K Sood, Gordon B. Mills. Copy Number Gain of has-miR-569
at 3q26.2 Leads to the Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell,
26(6): 863-79, 2014. PMC4261159
19. Sunila Pradeep, Seung W. Kim, Masato Nishimura, Chad V. Pecot, Pradeep Chaluvally-Raghavan,
Farideh Z. Bischoff, Julie Ann Mayer, Alpa M. Nick, Carolyn S. Hall, Edna M. Mora, Behrouz Zand,
Heather J. Dalton, Cristian Rodriguez-Aguayo, Thiru Arumugam, Takahito Miyake, Hee Dong Han,
Min Soon Cho, Rajesha Rupaimoole, Sherry Wu, Jinsong Liu, Robert L. Coleman, Gabriel Lopez-
Berestein, Isaiah J. Fidler, Anil K. Sood. Hematogenous metastasis of ovarian cancer relies on the
ErbB3/NRG axis. Cancer Cell, 26(1): 77-91, 2014. PMID 25026212, PMC4100212
20. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R,
Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS,
Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AK.
Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 74(12): 3282-93, 2014. PMID
24743243, PMC4058356
21. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C,
Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf
SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood
AK. Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell
Reports, 7(2): 488-500, 2014. PMID 24703838, PMC4038960
22. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM,
Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs
Curriculum Vitae
Revised 4/17/17 5
RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su
C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS,
Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2’-OMe-phophorodithioate-
modified siRNAs show increased loading into the RISC complex and enhanced anti-tumor activity.
Nature Communications, 5: 3459, 2014. PMID 24619206, PMC4112501
23. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, Pradeep S, Roh JW, Thanapprapasr D,
Dalton HJ, Pecot CV, Rupaimoole R, Lu C, Fellman B, Urbauer D, Kang Y, Jennings NB, Huang L,
Deavers MT, Broaddus R, Coleman RL, Sood AK. Cross-talk between EphA2 and BRaf/CRaf is a
key determinant of response to dasatinib. Clinical Cancer Research, 20(7): 1846-55, 2014. PMID
24486585, PMC3975695
24. Hyun Seok Kim, Saurabh Mendiratta, Jiyeon Kim, Chad V. Pecot, Jill E. Larsen, Iryna Zubovych,
Bo Yeun Seo, Jimi Kim, Banu Eskiocak, Hannah Chung, Elizabeth McMillan, Sherry Wu, Jef De
Brabander, Kakajan Kourov, Jason E. Toombs, Shuguang Wei, Michael Peyton, Noelle Williams,
Adi F. Gazdar, Bruce A. Posner, Rolf A. Brekken, Anil K. Sood, Ralph J. Deberardinis, Michael G.
Roth, John D. Minna, Michael A. White. Systematic Identification of Molecular Subtype-Selective
Vulnerabilities in Non-Small Cell Lung Cancer. Cell, 155(3): 552-66, 2013. PMID 24243015,
PMC3836195
25. Tao Liu, Wei Hu, Heather J. Dalton, Hyun Jin Choi, Jie Huang, Yu Kang, Sunila Pradeep, Takahito
Miyake, Jian H. Song, Yunfei Wen, Chunhua Lu, Chad V. Pecot, Justin Bottsford-Miller, Behrouz
Zand, Nicholas B. Jennings, Cristina Ivan, Gary E. Gallick, Keith A. Baggerly, David G. Hangauer,
Robert L. Coleman, Michael Frumovitz, Anil K. Sood. Targeting Src and tubulin in mucinous ovarian
carcinoma. Clinical Cancer Research, 19(23): 6532-43, 2013. PMID 24100628, PMC3852199
26. Yu Kang, Wei Hu, Cristina Ivan, Heather J. Dalton, Takahito Miyake, Chad V. Pecot, Behrouz
Zand, Tao Liu, Jie Huang, Nicolas B. Jennings, Rajesha Rupaimoole, Morgan Taylor, Sunila Pradeep,
Sherry Y. Wu, Chunhua Lu, Yunfei Wen, Jianfei Huang, Jinsong Liu, Anil K. Sood. Role of Focal
Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer. Journal of
the National Cancer Institute, 105(19): 1485-95, 2013. PMID 24062525, PMC3787907
27. Masato Nishimura, Eun-Jung Jung, Maitri Shah, Chunhua Lu, Riccardo Spizzo, Masayoshi Shimizu,
Hee Dong Han, Cristina Ivan, Simona Rossi, Xinna Zhang, Milena S. Nicoloso, Sherry Y. Wu, Justin
Bottsford-Miller, Chad V. Pecot, Behrouz Zand, Koji Matsuo, Mian M. Shazad, Nicholas B.
Jennings, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Anil K. Sood, George A. Calin.
Functional synergy between novel tumor suppressor miR-520d-3p and EphA2-targeting siRNA in
ovarian cancer. Cancer Discovery, 3(11): 1302-15, 2013. PMC3855315
28. Chad V. Pecot, Rajesha Rupaimoole, Da Yang, Rehan Akbani, Cristina Ivan, Chunhua Lu, Sherry
Wu, Hee-Dong Han, Maitri Y. Shah, Cristian Rodriguez-Aguayo, Justin Bottsford-Miller, Yuexin
Liu, Sang Bae Kim, Anna Unruh, Vianey Gonzalez-Villasana, Li Huang, Behrouz Zand, Myrthala
Moreno-Smith, Lingegowda S. Mangala, Morgan Taylor, Heather J. Dalton, Vasudha Sehgal, Yunfei
Wen, Yu Kang, Keith A. Baggerly, Ju-Seog Lee, Prahlad T. Ram, Murali K. Ravoori, Vikas Kundra,
Xinna Zhang, Rouba Ali-Fehmi, Ana Maria Gonzalez-Angulo, Pierre P. Massion, George A. Calin,
Gabriel Lopez-Berestein, Wei Zhang, Anil K. Sood. Tumor Angiogenesis Regulation by the miR-200
Family. Nature Communications, 4: 2427, 2013. PMID 24018975, PMC3787907
29. Da Yang, Yan Sun, Limei Hu, Hong Zheng, Ping Ji, Chad V. Pecot, Yanrui Zhao, Sheila Reynolds,
Hanyin Cheng, Rajesha Rupaimoole, David Cogdell, Matti Nykter, Russell Broaddus, Cristian
Rodriguez-Aguayo, Gabriel Lopez-Berestein, Jinsong Liu, Ilya Shmulevich, Anil K. Sood, Kexin
Chen, Wei Zhang. Integrated analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell, 23 (2): 186-99, 2013. PMID 23410973,
PMC3603369
Curriculum Vitae
Revised 4/17/17 6
30. Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, Auzenne E, Lopez-Araujo A,
Lu C, Nishimura M, Pecot CV, Zand B, Thanapprapa D Sr, Jennings NB, Kang Y, Huang J, Hu W,
Klostergaard J, Sood AK. Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in
Ovarian Carcinoma. Clinical Cancer Research, 18(15): 4114-21, 2012. PMID 22693353,
PMC3638880
31. Chad V. Pecot, Ming Li, Xueqiong J. Zhang, Rama Rajanbabus, Ciara Calitri, Aaron Bungum,
James R. Jett, Joe B. Putnam, Carol Callaway-Lane, Steve Deppen, Eric L. Grogan, David P.
Carbone, John A. Worrells, Karel G.M. Moons, Yu Shyr, Pierre Massion. Added Value of a Serum
Proteomic Signature in the Diagnostic Evaluation of Lung Nodules. Cancer Epidemiology,
Biomarkers & Prevention, (5): 786-92, 2012. PMC3660018
32. Rebecca L. Stone, Alpa M. Nick, Iain A. McNeish, Frances Balkwill, Hee Dong Han, Justin
Bottsford-Miller, Rajesha Rupaimoole, Guillermo N. Armaiz-Pena, Chad V. Pecot, Jermaine
Coward, Michael T. Deavers, Hernan G. Vasquez, Diana Urbauer, Charles N. Landen, Wei Hu,
Hannah Gershenson, Koji Matsuo, Mian M.K. Shahzad, Erin R. King, Ibrahim Tekedereli, Bulent
Ozpolat, Edward H. Ahn, Virginia K. Bond, Rui Wang, Angela F. Drew, Francisca Gushiken,
Katherine Collins, Koen DeGeest, Susan K. Lutgendorf, Wah Chiu, Gabriel Lopez-Berestein, Vahid
Afshar-Kharghan, Anil K. Sood. Paraneoplastic Thrombocytosis in Ovarian Cancer. New England
Journal of Medicine, 16, 366(7): 610-618, 2012. PMID 22335738, PMC3296780
33. Chad V. Pecot, Farideh Z. Bischoff, Julie Ann Mayer, Karina L. Wong, Tam Pham, Justin Bottsford-
Miller, Rebecca L. Stone, Yvonne G. Lin, Padmavathi Jaladurgam, Ju Won Roh, Blake W. Goodman,
William M. Merritt, Tony J. Pircher, Stephen D. Mikolajczyk, Alpa M. Nick, Joseph Celestino, Cathy
Eng, Lee M. Ellis, Michael T. Deavers and Anil K. Sood. Novel Platform for detection of CK+ and
CK- CTCs. Cancer Discovery 1:580-586, 2011. PMID 22180853, PMC3237635
34. Mian M.K. Shahzad, Lingegowda S. Mangala, Hee Dong Han, Chunhua Lu, Justin Bottsford-Miller,
Masato Nishimura, Edna M. Mora, Jeong-Won Lee, Rebecca L. Stone, Chad V. Pecot, Duangmani
Thanapprapasr, Ju-Won Roh, Puja Gaur, Maya P. Nair, Yun-Yong Park, Nirupama Sabnis, Michael
T. Deavers, Ju-Seog Lee, Lee M. Ellis, Gabriel Lopez-Berestein, Walter J. McConathy, Laszlo
Prokai, Andras G. Lacko and Anil K. Sood. Targeted Delivery of Small Interfering RNA Using
Reconstituted High-Density Lipoprotein Nanoparticles. Neoplasia 13(4): 1-11, 2011. PMID
21472135, PMC3071079
35. Chad V. Pecot, George A. Calin, Robert L. Coleman, Gabriel Lopez-Berestein Anil K. Sood. RNA
Interference in the Clinic: Challenges and Future Directions. Nature Reviews Cancer 11(1):59-67,
2011. (Cover Illustration) PMID 21160526, PMC3199132
36. Grogan EL, Deppen S, Pecot CV, Putnam JB, Nesbitt JC, Shyr Y, Rajanbabu R, Ory B, Lambright
ES, Massion PP. Diagnostic characteristics of a serum biomarker in patients with positron emission
tomography scans. Annals of Thoracic Surgery 89 (6):1724-8, 2010. PMID: 20494018,
PMC3026702
37. Pecot CV, Fuller M, Muldowney JAS III, Misra S. A Very Late Stent Thrombosis in a Patient with
Diabetes: A Call for Lifelong Dual Anti-Platelet Therapy. Tennessee Medicine 102 (5): 37-39, 2009.
PMID: 19456028
Abstracts
1. Alessandro Porrello, Patrick Leslie, Emily Harrison, Salma Azam, Virginia Godfrey, Shelley Earp,
Chad V. Pecot. Targeting Inflammatory Monocytes in Lung Squamous Carcinoma. ASCO Scientific
Developmental Retreat, 2016.
2. Romina González-Pons, Christian Lagares-Linares, Tatiana Ortiz, Chad V. Pecot, Guillermo N.
Armaiz-Peña. Increased GR and ADRB2 Expression is Associated with Metastatic Behavior in an
Curriculum Vitae
Revised 4/17/17 7
Orthotopic Model of Lung Squamous Carcinoma. Annual Biomedical Research Conference for
Minority Student, 2016.
3. Salma H. Azam, Alessandro Porrello, Xinan Liu, Jinze Liu, Chad V. Pecot. A Novel
microRNA/RNA-Binding Protein Axis of Regulation in Tumor Endothelial Cell Function. UNC
Annual Lineberger Scientific Retreat, 2016.
4. Anne Y. Feng, Chad V. Pecot. Novel Mutant-Specific siRNAs induce selective mutant KRAS
knock-down. UNC Undergraduate Biology Symposium, 2016.
5. Salma H. Azam, Alessandro Porrello, Trent Waugh, Chad V. Pecot. The Roles of microRNA-200
and the RNA Binding Protein Quaking in Regulating Tumor Angiogenesis. UNC Translational
Medicine Symposium, 2016. *Won Second Place Prize
6. Adam Belanger, Alessandro Porrello, Salma Azam, Subrata Ghosh, Trent Waugh, Mitchell Smith,
Chad V. Pecot. Novel Regulators of Metastases in Lung Squamous Carcinoma. American Thoracic
Society, 2016 (#5702). *Selected for Poster Discussion Session
7. Salma Azam, Seth Miller, Trent Waugh, Sarah Shelton, Vivek Somasundaram, Mitchell Smith, Paul
Dayton, Adrienne D. Cox, Chad V. Pecot. Effects of Vascular Normalization when combining miR-
200b with Radiation. UNC Translational Medicine Symposium, 2015.
8. Adam Belanger, Alessandro Porrello, Salma Azam, Trent Waugh, Mitchell Smith, Chad V. Pecot.
MicroRNA Regulators of Lymph Node Metastasis in Lung Squamous Cell Carcinoma. Visiting
Pulmonary Scholar Program, 2015. *Won First Place Prize
9. Salma Azam, Alessandro Porrello, Trent Waugh, James McCann, Chad V. Pecot. MicroRNA-200b
Regulates Tumor Angiogenesis via inhibition of QKI. UNC Interdisciplinary Vascular Biology
Symposium, 2015.
10. Salma Azam, Seth Miller, Trent Waugh, Vivek Somasundaram, Mitchell Smith, Adrienne D. Cox,
Chad V. Pecot. Effects of Vascular Normalization when combining miR-200b with Radiation.
AACR Tumor Angiogenesis and Vascular Normalization: Bench to Bedside to Biomarkers meeting,
2015.
11. Mitchell Smith, Trent Waugh, Blake Albright, Salma Azam, James McCann, Virginia Godfrey, Chad
V. Pecot. A Smoking (Hot) Model of Lung Cancer: Squamous Histology, Metastatic Properties,
Immune-competent Background. UNC Lineberger Annual Scientific Retreat, 2014. *3rd
Place Prize
for Translational Research
12. Chad V. Pecot, Sherry Wu, Seth Bellister, Rajat Bhattacharya, Anshumaan Maharaj, Cristian
Rodriguez-Aguayo, Vianey Gonzalez-Villasana, Rajesh Rupaimoole, Gabriel Lopez, Lee M. Ellis,
Anil K. Sood. Therapeutic KRAS Silencing in Lung and Colon Cancer Models. Poster Session,
AACR Special Conference, RAS Oncogenes: From Biology to Therapy, 2014.
13. Chad V. Pecot, Anshumaan Maharaj, Sherry Wu, Cristian Rodriguez-Aguayo, Vianey Gonzalez-
Villasana, Rajesh Rupaimoole, Behrouz Zand, Thiru Arumugam, Gabriel Lopez, Anil K. Sood.
Silencing the Elephant in the Room: Therapeutic KRAS targeting with siRNA. Poster Session,
American Association of Cancer Research, 2013 (#938).
14. Sunila Pradeep, Kim Wook, Masato Nishimura, Pradeep Raghavan, Chad V. Pecot, Gabriel Lopez,
Isaiah Fidler, Anil Sood. Hematogenous metastasis in ovarian cancer: Importance of the ErbB3/NRG
axis. Poster Session, American Association of Cancer Research, 2013 (#408).
15. Sherry Y. Wu, Anna K. Unruh, Rajesha Rupaimoole, Cristina Ivan, Dennis Ruder, Sunila Pradeep,
Vasudha Sehgal, Cristian Rodriguez-Aguayo, Chad V. Pecot, Takahito Miyake, Gabriel Lopez-
Curriculum Vitae
Revised 4/17/17 8
Berestein, Prahlad Ram, Keith A. Baggerly, Anil K. Sood. Overcoming platinum-resistance in
ovarian cancer via targeting basonuclin1 (BNC1). Poster Session, American Association of Cancer
Research, 2013 (#2036).
16. Rajesha Rupaimoole, Sunila Pradeep, Anna Unruh, Archana S. Nagaraja, Chad V. Pecot, Sherry Y.
Wu, Behrouz Zand, Heather J. Dalton, Cristina Ivan, Wei Zhang, Anil K. Sood. A novel mechanism
of hypoxia-mediated cell cycle dysregulation: miR-134 targets CDKN2A. Poster Session, American
Association of Cancer Research, 2013 (#3091).
17. Heather J. Dalton, Cristina Ivan, Chad V. Pecot, Rajesha Rupamaiole, Behrouz Zand, Justin
Bottsford-Miller, Wei Hu, Alpa M. Nick, Robert L. Coleman, Anil K. Sood. An integrated analysis of
the eph/ephrin family: implications in endometrial cancer. Poster Session, American Association of
Cancer Research, 2013 (#4034).
18. Behrouz Zand, Cristina Ivan, Chad V. Pecot, Rajesha Rupaimoole, Heather J. Dalton, Justin
Bottsford-Miller, Wei Hu, Alpa M. Nick, Anil K. Sood. Ten degrees of separation: novel genes
affecting outcome in ovarian cancer. Poster Session, American Association of Cancer Research, 2013
(#4024).
19. Behrouz Zand, Cristina Ivan, Chad V. Pecot, Rajesha Rupaimoole, Heather Dalton, Justin Bottsford-
Miller, Wei Hu, Alpa M. Nick, Anil K. Sood. Deception of suppression: Unexpected effects of
Tristetraprolin in ovarian cancer. Poster Session, Society of Gynecology Oncology, 2012.
20. Chad V. Pecot, Rehan Akbani, Cristina Ivan, Anna K. Unruh, Sherry Wu, Rajesh Rupaimoole, Justin
Bottsford-Miller, Behrouz Zand, Susan L. Tucker, Robert L. Coleman, Keith A. Baggerly, Anil K.
Sood. Clinical Relevance of miR-200 Family Members in Various Cancers. Poster Session, American
Association of Cancer Research, 2012 (#3157).
21. Rajesha Rupaimoole, Chad V. Pecot, Sherry Y. Wu, Justin Bottsford-Miller, Cristina Ivan, Wei
Zhang, Robert L. Coleman and Anil K. Sood. A novel mechanism of hypoxia mediated cell cycle
dysregulation: miR-134 targets CDKN2A. Poster Session, American Association of Cancer Research,
2012 (#178).
22. Sherry Y. Wu, Anna K. Unruh, Geoffrey Bartholomeusz, Cristina Ivan, Chad V. Pecot, Rajesha
Rupaimoole, Hee-Dong Han, Justin Bottsford-Miller, Susan L. Tucker, Robert L. Coleman, Gabriel
Lopez-Berestein, Keith A. Baggerly, and Anil K. Sood. Basonuclin 1 (BNC1): A novel therapeutic
target in ovarian cancer identified through integrative TCGA-based functional genomic analysis.
Poster Session, American Association of Cancer Research, 2012 (#884).
23. Yunfei Wen, Behrouz Zand, Kang Yu, Justin Bottsford-Miller, Rebbeca L. Stone, Amy Carroll,
Chad V. Pecot, Sunila Pradeep, Sherry Wu, Wei Hu, Bulent Ozpolat, Robert Coleman, Anil K. Sood.
Suicidal tendencies: The promotion of cell death by a prolactin antagonist through autophagy in
ovarian cancer. Poster Session, American Association of Cancer Research, 2012 (#2268).
24. Justin Bottsford-Miller, Rebecca Stone, Alpa Nick, Behrouz Zand, Chad V. Pecot, Cristina Ivan,
Wei Hu, Robert L. Coleman, Vahid Afshar-Khargan, Anil K. Sood. Contribution of malignant
thrombocytosis to ovarian cancer proliferation and resistance to chemotherapy-induced-apoptosis
through Platelet Derived Growth Factor Receptor-Alpha (PDGFRA) signaling. Poster Session,
American Association of Cancer Research, 2012 (#4367).
25. Heather J. Dalton, Christina Ivan, Chad V. Pecot, Rajesha Rupamaiole, Behrouz Zand, Justin
Bottsford-Miller, Wei Hu, Alpa M. Nick, Robert L. Coleman, Anil K. Sood. The Eph Family: Not
Playing Nice in Uterine Cancer. Poster Session, Society of Gynecology Oncology, 2012.
Curriculum Vitae
Revised 4/17/17 9
26. Behrouz Zand, Cristina Ivan, Chad V. Pecot, Rajesha Rupaimoole, Heather Dalton, Justin Bottsford-
Miller, Wei Hu, Alpa M. Nick, Anil K. Sood. Separating the good, the bad, and the ugly: New
directions in genomic prediction of outcome in ovarian cancer. Poster Session, Society of
Gynecology Oncology, 2012.
27. Justin Bottsford-Miller, Rebecca L. Stone, Alpa M. Nick, Behrouz Zand, Chad V. Pecot, Christina
Ivan, Wei Hu, Vahid Afshar-Kharghan, Anil K. Sood. Fuel on the fire: Contribution of
thrombocytosis to ovarian cancer resistance to taxane-based chemotherapy. Society of Gynecology
Oncology, 2012.
28. Chad V. Pecot, Farideh Bischoff, Yvonne G. Lin, Padmavathi Jaladurgam, William Merritt, Tony
Pircher, Steve Mikolajczyk, Julie Mayer, Karina Wong, Tam Pham, Justin Bottsford-Miller, Rebecca
Stone, Joseph Celestino, Alpa Nick, Cathy Eng, Anil K. Sood. Redefining CTCs: Detection of
cytokeratin-negative circulating tumor cells (CTCs). Poster Session, American Association of Cancer
Research, 2011 (#1553).
29. Edna M. Mora, Chad V. Pecot, Lingegowda S. Mangala, Hee Dong Han, Pablo Vivas-Mejias,
Bokyung Sung, Masato Nishimura, Koji Matsuo, Sankar Kannan, Patrick A. Zweidler-McKay, Rene
Nieves Alicea, Guillermo N. Armaiz-Peña, Mian M.K. Shahzad, Shyon Haghpeykar, Alpa M. Nick,
Rebecca L. Stone, Jinsong Liu, Wei Hu, Bharat B. Aggarwal, Gabriel López Berestein, David
Jackson, Anil K. Sood. Erythropoietin Met a New Rector. Poster Session, American Association of
Cancer Research, 2011 (#1618).
30. Alpa M. Nick, Rebecca L. Stone, Bin Chang, Jinsong Liu, Diana Urbauer, Edna M. Mora, Chad V.
Pecot, Lingegowda S. Mangala, Hee Dong Han, Pablo Vivas-Mejias, Bokyung Sung, Masato
Nishimura, Koji Matsuo, Sankar Kannan, Patrick A. Zweidler-McKay, Rene Nieves Alicea,
Guillermo N. Armaiz-Peña, Mian M.K. Shahzad, Shyon Haghpeykar, Wei Hu ,Bharat B. Aggarwal,
Gabriel López Berestein, David Jackson, Anil K. Sood. In Search of a Novel EPO Receptor: The
Clinical Significance of the Ephrin Connection. Poster Session, American Association of Cancer
Research, 2011 (#4457).
31. Justin Bottsford-Miller, Angela Sanguino, Duangmani Thanapprapasr, Chad V. Pecot, Rebecca L.
Stone, Kurt Auger, Alpa M. Nick, Anil K. Sood. Enhancing anti-angiogenic therapy by blocking
focal adhesion kinase. Late-breaking Poster Session, American Association of Cancer Research, 2011
(#LB-230).
32. Chad V. Pecot, Farideh Z. Bischoff, Yvonne G. Lin, Padmavathi Jaladurgam, William Merritt, Tony
Pircher, Steve Mikolajczyk, Julie Ann Mayer, Karina Wong, Tam Pham, Justin Bottsford-Miller,
Rebecca Stone, Joseph Celestino, Alpa Nick, Cathy Eng, Anil K. Sood. Clinical relevance of
cytokeratin-negative circulating tumor cells. Electronic Publication, American Society of Clinical
Oncology, 2011 (#e21101).
33. Chad Pecot, Xueqiong Zhang, Rama Rajanbabu, Ming Li, James R. Jett, Eric L Grogan, David P.
Carbone, Yu Shyr, Pierre P. Massion. Value of a Serum Proteomic Signature in the Non-Invasive
Evaluation of Lung Nodules. Poster Discussion Session, American Society of Clinical Oncology
Annual Meeting, 2010 (#10520).
34. Eric L. Grogan, MD, MPH, Stephen Deppen, MA, MS, Chad Pecot, MD, Yu Shyr, PhD, Rama
Rajanbabu, MS, Bill Putnam, MD, Eric S. Lambright, MD, Jon Nesbitt, MD, Pierre P. Massion, MD.
Role of a serum proteomic signature in the management of pulmonary nodules. Southern Thoracic
Surgical Association Meeting, 2009.
35. Chad V. Pecot, Jun Qian, Pierre P. Massion. Effect of Silencing hTERC expression in Non-Small
Cell Lung Cancer on Cellular Proliferation. Vanderbilt-Ingram Cancer Center Retreat, 2009.
Curriculum Vitae
Revised 4/17/17 10
36. C Pecot, R Rajanbabu, X Zhang, M Li, B Ory, JR Jett, JB Putnam, EL Grogan, RM Caprioli, DP
Carbone, KG Moons, Y Shyr, PP Massion. Added value of serum MALDI MS signature to clinical
and imaging predictors of early stage lung cancer. Strategic Partnering to Evaluate Cancer Signatures
(SPECS) Annual Meeting, 2008.
Patents
1. U.S. Provisional Application Number 62/280,458 Filed January 19th, 2016
UNC Reference 16-0006, MB&S Reference 5470.773PR
“Methods and compositions using RNA Interference for inhibition of KRAS”
Teaching and Service
Hospital and Cancer Center Committees:
Animal Studies Core Advisory Committee July 2014 – present
Protocol Review Committee August 2014–present
Infusion Center APP Search Committee February 2015 – present
Fellowship Education Committee June 2015 – present
Service to the University of North Carolina:
Judge: LCCC 38th Annual Postdoc-Faculty Research Day September 2013
Faculty Advisor for Triangle Church Campus Ministry August 2013 – present
Judge: 46th Annual Medical Student Research Day January 2014
Judge: 47th Annual Medical Student Research Day January 2015
Faculty Mentor for Carolina Covenant Scholars August 2014 – present
Judge: Translational Medicine and Cancer Biology Training Program April 2017
Service Outside the University of North Carolina:
Scientific Advisory Committee for Lung Cancer Initiative of NC December 2016 – present
Graduate Student Thesis Committees:
Salma H. Azam Chad Pecot Laboratory June 2015 – present
James V. McCann Andrew Dudley Laboratory June 2015 – present
Myung Soo Kim Elena Batrakova Laboratory January 2015 – April 2016
Alicia Tagliatela James Bear Laboratory October 2016 – present
Grant Study Sections:
UNC University Cancer Research Fund November 2015 – present
Formal Teaching:
Invited Speaker: UNC Lineberger Cancer Center 41st Annual Symposium May 2017
“Integrated Approaches to Uncover Metastatic Biology”
MOPH 868 Course: Advances in Drug Delivery and Nano-Medicine November 2016
“Nano Cancer Theranostics in Clinical Development”
GRACE Webinar Series: Not Your Father’s Lung Squamous Cancer” November 2016
Curriculum Vitae
Revised 4/17/17 11
“Future Directions in the Treatment of Squamous Lung Cancer?”
GRACE Webinar Series: Not Your Father’s Lung Squamous Cancer” November 2016
“What is Squamous Lung Cancer?”
T32 Nanotechnology Course September 2016
“What Scientists can learn from Clinical Trials in Cancer”
Invited Speaker: UNC Rex Hospital July 2016
“2016 Best of ASCO Lung Cancer Updates”
Invited Speaker: UNC’s Immune-Genomics Working Group July 2016
“Targeting Monocytes to Block Lung Squamous Metastasis”
Invited Speaker: American Thoracic Society May 2016
“Treating YOU: Targeted Therapy and Immunotherapy in Lung Cancer”
Hematology/Oncology Fellow Lecture April 2016
“The Hallmarks of Cancer”
Invited Speaker: Ponce Health Sciences University January 2016
“Extinguishing Metastatic Biology”
Invited Speaker: UNC Hematology/Oncology Division Scientific Retreat October 2015
“Targeting Metastatic Biology with RNA Interference”
Invited Speaker: Banner-MDA Southwest Lung Cancer Symposium March 2015
“Adjuvant Chemotherapy In Non-Small Cell Lung Cancer”
Invited Speaker: 15th Annual Targeted Therapies in Lung Cancer February 2015
“Therapeutic KRAS Silencing with RNA Interference”
Invited Speaker: Cancer Grace Webinar Series January 2015
“Lung Squamous Cancer, 201”
Invited Speaker: The 2nd Annual Summit on Lung Cancer December 2014
“Using RNA Interference to Control Lung Cancer Metastases”
Invited Speaker: Waun Ki Hong Festschrift Retirement Celebration August 2014
“From Bed to Bedside to Bench”
Invited Lecture: Johns Hopkins Lung Cancer Update June 2014
“Immunotherapy and Nanotechnology in Lung Cancer”
Invited Lecture: Annual Lineberger Scientific Retreat May 2014
“Therapeutic Vascular Normalization with Novel AngiomiRs”
Molecular Therapeutics Program Retreat November 2013
“Altering Tumor Biology with Therapeutic RNA Interference”
Curriculum Vitae
Revised 4/17/17 12
2013 Geriatric Oncology Retreat: Cancer, Aging And Resilience November 2013
“Lung Cancer Treatment in the Elderly, An Evolving Paradigm”
Invited Lecture: UNC Lineberger Comprehensive Cancer Center January 2013
“Divergent Clinical Outcomes of the miR-200 Family via Angiogenesis Regulation”
Invited Lecture: Ohio State The James Cancer Center December 2012
“Divergent Clinical Outcomes of the miR-200 Family via Novel Pathway Regulation”
Invited Lecture: Vanderbilt Ingram Cancer Center December 2012
“Therapeutic RNA Interference: Unlocking the Potential”
Invited Lecture: UTSW Simmons Cancer Center November 2012
“Therapeutic RNA Interference: Unlocking the Potential”
Invited Lecture: Emory’s Winship Cancer Institute November 2012
“Divergent Clinical Outcomes of the miR-200 Family via Novel Pathway Regulation”
Invited Lecture: W.M. Keck Research Conference July 2012
“Divergent Clinical Outcomes of the miR-200 Family via Novel Pathway Regulation”
Invited Lecture: MDACC Institutional Grand Rounds April 2012
“Divergent Roles of the miR-200 Family: Regulation of Angiogenesis Networks”
Invited Lecture: MDACC Department of Thoracic Oncology April 2012
“RNA Interference: From the Bench to the Bedside”
Invited Lecture: Isaiah J. Fidler Metastasis Research Retreat December 2011
“Redefining CTCs: Detection of Cytokeratin-Negative CTCs”
Lung Cancer Lecture Series (U.T. Residency Program) November 2011
Department of Cancer Medicine Grand Rounds: MDACC May 2011
“Redefining CTCs: Detection of Cytokeratin-Negative CTCs”
Invited Lecture: Stand-Up to Cancer Program, Thoracic Oncology April 2011
“Redefining CTCs: Detection of Cytokeratin-Negative CTCs”
Invited Lecture: Department of Cancer Biology March 2011
“Redefining CTCs: Detection of Cytokeratin-Negative CTCs”
Mentorship (Trainee Accomplishments)
UNC Undergraduate Students Major Month/Year(s)
Mitchell Smith Biology 9/2013-8/2015
(2014 LCCC Scientific Retreat, 3rd
Place Prize for Translational Research)
Vivek Somasundaram Biomedical Engineering 5/2014-5/2016
(2015 NIH Biomedical Engineering Summer Internship Program)
Anne Feng Biology 1/2015-present
(2016 Summer Undergraduate Research Fellowship Awardee)
Curriculum Vitae
Revised 4/17/17 13
(William and Ida Taylor Honors Mentored Research Fellowship)
(2017 Irvine R. Hagadorn Award-Given by the Chancellor to the Top Biology Student)
Monal Depani Biology 6/2016-present
Gabriella Yacavone Biology 6/2016-present
Nick Mckenzie Biostatistics and Mathematics 6/2016-present
UNC Residents and Fellows Specialty Month/Year(s)
Seth Miller, M.D. Radiation Oncology 9/2013-3/2014
Adam Belanger, M.D. Pulmonary 5/2014-present
(2015 ASCO Conquer Cancer Foundation Young Investigator Award)
(2015 North Carolina Lung Cancer Initiative Fellowship Award)
(2015 1st Place Prize in Visiting Pulmonary Scholars Poster Competition)
Sanggyu Bae, M.D. Oncology 1/2015-present
(2016 North Carolina Lung Cancer Initiative Fellowship Award)
UNC Graduate Program in the Genetics Curriculum Month/Year(s)
James McCann Winter Rotation 1/2014-3/2014
Blake Albright Spring Rotation 3/2014-5/2014
Salma Azam Joined Lab 3/2014-present
(2014 NIH Genetics T32 Training Grant Award)
(2016 Translational Medicine Symposium 2nd
Place Prize)
(2017 ImPACT Internship)
Sravya Kattula Spring Rotation 2/2015-4/2015
Nate Diehl Summer Rotation 7/2016-8/2016
Post-Doctorate Fellows Current Position Month/Year(s)
Alessandro Porrello Senior Bioinformatics Specialist 3/2014-present
Subrata Ghosh Senior Research Scientist 7/2014-7/2016
Adolfo Alfonso Industry (GlaxoSmithKline) 10/2014-6/2015
Emily Harrison Post-Doctorate 6/2016-present
(T32 Nanotechnology Post-Doctorate Fellowship)
Patrick Leslie Post-Doctorate 8/2016-present
(2017 ImPACT Internship)
Balachandra Gorentla Post-Doctorate 4/2017-present
Grants – past 5 years
Ongoing
ACS MRSG-14-222-01-RMC Pecot (PI) 01/01/2015-12/31/2019 5.40 Calendar (45.00%)
Tumor Angiogenesis Regulation by the miR-200 Family 134,976.00
The goal of this proposal is to uncover novel mechanisms by which the miR-200 family regulates tumor
angiogenesis and the temporal association this has with deregulated angiogenesis.
Role: Principal Investigator
Stuart Scott Foundation (TVF/LCI) Pecot (PI) 11/01/2016-10/31/2017 1.8 Calendar (15.00%)
Targeting the Immune Microenvironment to Treat Squamous Cancers 200,000.00
The goal of this proposal is to recruit African-American patients with lung and head/neck squamous
cancers onto our clinical trial portfolio using immune-checkpoint inhibitors. We perform RNA-seq
analysis and assess the predictive power of a gene signature we have developed.
Role: Principle Investigator
Curriculum Vitae
Revised 4/17/17 14
Lung Cancer Research Foundation Pecot (PI) 11/01/2016-10/31/2018 1.2 Calendar (10.00%)
Targeting Lung Squamous Metastasis with CCR2 Inhibitors 75,000.00
The goal of this proposal is to test a novel CCR2 inhibitor for its ability to inhibit lung squamous cancer
metastasis in novel mouse models we have developed. We will also develop and immunohistochemistry
staining protocol for use in subsequent clinical trials.
Role: Principle Investigator
Free to Breathe Metastasis Research Pecot (PI) 01/01/2017-12/31/2019 1.2 Calendar (10.00%)
Targeting Lung Squamous Metastasis with CCR2 Inhibitors 133,333.33
The goal of this proposal is to test a novel CCR2 inhibitor for its ability to inhibit lung squamous cancer
metastasis in novel mouse models we have developed. We will also develop and immunohistochemistry
staining protocol for use in subsequent clinical trials.
Role: Principle Investigator
University Cancer Research Fund Pecot (PI) 08/01/2013-07/31/2018 0.00 Calendar (0.00%)
RNA-interference Approaches to target Lung Cancer Metastases
The goal of these funds is to develop novel strategies to inhibit lung cancer metastasis using RNA-
interference approaches.
Role: Principal Investigator
Susan G. Komen Catalyst Award Pecot (PI) 09/30/2017-09/30/2020 1.2 Calendar (10.00%)
Susan G. Komen Foundation 150,000.00
HDAC11 Promotes Breast Cancer Metastasis via the Lymphatic Route
This proposal will focus on the role HDAC11 has in regulating the development of lymphatic and distant
metastasis in triple-negative breast cancer. We will focus on mechanistic roles of HDAC11, as well as
potential therapeutic approaches to shut down this metastatic route of spread.
Role: Principal Investigator
UCRF Innovator Award Pecot (PI) 07/01/2015-06/30/2017 0.00 Calendar (0.00%)
Lineberger Comprehensive Cancer Center 100,000.00
Fate-Mapping Cancer Cells from Lymph Nodes to Uncover Novel Metastatic Biology
This proposal seeks to challenge the metastatic cascade paradigm that largely assumes cancer spreads by
direct hematogenous entry. We will employ novel models we’ve developed to investigate the relative
contributions lymphatic metastases have on distant metastases.
Role: Principal Investigator
2-RO1-CA042978-29A1 Der (PI) 07/01/2015-06/30/2020 0.60 Calendar (5.00%)
National Cancer Institute 368,685.00
Biological Activity of Ras Oncogenes
The goal of these funds will be to investigate the roles of several downstream targets of mutant KRas on
invasion and metastasis development. I will be involved in all animal modeling and therapeutic
assessments.
Role: Co-Investigator
U54-CA198999-01 Huang (PI) 08/01/2015-07/31/2020 0.60 Calendar (5.00%)
National Cancer Institute (CCNE) 343,636.00
Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer The goal of these funds will be to test several polymeric micelle formulations for their ability to deliver
highly toxic and insoluble drugs. I will specifically be evaluating these formulations in murine models of
lung cancer.
Curriculum Vitae
Revised 4/17/17 15
Role: Co-Investigator
Completed V Foundation (Pecot) 11/1/2014-10/31/2016 1.80 Calendar (15.00%)
Jimmy V Foundation Scholar Award 99,786.00
Tumor Angiogenesis Regulation by the miR-200 Family
The goal of this proposal is to uncover novel mechanisms by which the miR-200 family regulates tumor
angiogenesis and the temporal association this has with deregulated angiogenesis.
Young Investigator Award (Pecot) 07/01/2011-06/30/2012 0.00 Calendar (0.00%)
ASCO Conquer Cancer Foundation 50,000.00
Therapeutic miRNA targeting for Lung Cancer Metastases
The funding enabled the exploration of novel mechanisms used by the miR-200 family for lung cancer
metastases, and to test the therapeutic efficacy of nanoparticle delivered miR-200 members in inhibiting
cancer metastases. This resulted in the discovery that the miR-200 family inhibits tumor angiogenesis and
has pronounced therapeutic potential in several cancer types (Pecot et al, Nature Communications, 2013).
Professional Service
Faculty Advisor for Triangle Church Campus Ministry 2013-present
American Association for Cancer Research 2010-present
American Society of Clinical Oncology 2009-present
Alpha Omega Alpha 2006-present
Christian Medical and Dental Association 2002-present
Peer-Reviewer
Journal of Clinical Investigation
Clinical Cancer Research
Cancer
Gynecology Oncology
Oncogene
Stem Cells
Teaching Summary Statement
As a college student at the age of twenty I was diagnosed with Stage II mixed embryonal carcinoma and
seminoma. Following surgery and three rounds of chemotherapy I have since been cured, leaving an
indelible impression on me that I must “give back” and make a difference for other cancer patients.
Since August 2013 I have been an Assistant Professor at the UNC Lineberger Comprehensive Cancer
Center and I specialize in thoracic malignancies. I credit much of my teaching philosophy and style to my
personal medical oncologist, Professor Pasquale Benedetto of the University of Miami. While receiving
treatment from Dr. Benedetto, known as Dr. “B”, I was truly inspired by his infectious passion as he’d
entertain my curiosities surrounding cancer. This personal experience, coupled with my desire to care for
the other patients sitting alongside me in the waiting rooms led me to change my career path as a
Biomedical Engineer towards becoming a Medical Oncologist. Within months I was accepted into
Miami’s fast-track Medical Scholars program, and Dr. B became my mentor throughout medical school.
I have long believed that one learns best when they enjoy the topic. For this reason I think it is imperative
that I teach with enthusiasm and excitement, and my teaching evaluations to date from medical students,
medicine residents and oncology fellows reflect this. Furthermore, when giving formal presentations,
whether at UNC or a national conference, I try to take a more “outside of the box” approach by
Curriculum Vitae
Revised 4/17/17 16
challenging the status quo mentality. Almost as a personal rule, my presentations rarely have bullet
points, are filled with attention grabbing titles and graphics, and I always aim to throw in a few
provocative concepts peppered throughout the talk. The intended consequence is to stimulate thinking,
excitement and conversation, the ultimate goal being to effectuate change.
As detailed in my research summary statement, my goal is focus on eliminating the cause of death of
most cancer patients, which is our inability to control metastatic biology. Although my research
accomplishments thus far have enabled me to give some notable lectures, my vision going forward is that
my research efforts will lead too much greater discoveries and invitations to share such findings on a
national and international level. Such success would imply that indeed we are well on our way to making
a difference for those suffering from cancer.
Research Summary Statement
Because my passion began as a cancer patient, I am constantly driven to uncover important findings in
cancer biology and translate these to the clinic as rapidly as possible. I have 7 years of formal experience
in basic science studying cancer biology, the first three began in August 2010 as a medical oncology
fellow in Dr. Anil Sood’s laboratory (MD Anderson Cancer Center, Houston, TX), and since August
2013 I have been an independent investigator at the University of North Carolina, Chapel Hill. My
research career thus far has quickly led to several high-impact discoveries by combining innovative ideas
and synergistic collaborative teams. My research is characterized by a harmonization of therapeutic
RNA interference, sophisticated modeling of cancer metastasis and the tumor microenvironment, and
the integrative use of bioinformatics platforms and systems biology to uncover key nodes in cancer
networks. Because lung cancer accounts for the greatest proportion of cancer-related deaths in the U.S.
and worldwide, which is almost invariably due to metastatic spread, most of my current work uses lung
cancer as a disease model with the hopes that our discoveries will also fundamentally impact paradigms in
other malignancies.
